MX2017016910A - Tratamiento del deterioro del modo de andar y de las extremidades y del trastorno de procesamiento de la corteza pre-frontal. - Google Patents
Tratamiento del deterioro del modo de andar y de las extremidades y del trastorno de procesamiento de la corteza pre-frontal.Info
- Publication number
- MX2017016910A MX2017016910A MX2017016910A MX2017016910A MX2017016910A MX 2017016910 A MX2017016910 A MX 2017016910A MX 2017016910 A MX2017016910 A MX 2017016910A MX 2017016910 A MX2017016910 A MX 2017016910A MX 2017016910 A MX2017016910 A MX 2017016910A
- Authority
- MX
- Mexico
- Prior art keywords
- gait
- frontal cortex
- limb impairment
- processing disorder
- cortex processing
- Prior art date
Links
- 230000006735 deficit Effects 0.000 title abstract 2
- 230000005021 gait Effects 0.000 title abstract 2
- 210000002442 prefrontal cortex Anatomy 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000009575 Angelman syndrome Diseases 0.000 abstract 1
- 208000001914 Fragile X syndrome Diseases 0.000 abstract 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 abstract 1
- 208000006289 Rett Syndrome Diseases 0.000 abstract 1
- 206010008129 cerebral palsy Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960001344 methylphenidate Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/793,829 US9307942B2 (en) | 2011-05-19 | 2015-07-08 | Treatment for cerebral palsy gait impairment |
| US14/881,516 US9333198B2 (en) | 2011-05-19 | 2015-10-13 | Treatment for cerebral palsy gait impairment |
| US14/971,325 US9408838B2 (en) | 2011-05-19 | 2015-12-16 | Treatment for cerebral palsy gait impairment |
| US15/075,375 US9682073B2 (en) | 2011-05-19 | 2016-03-21 | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| PCT/US2016/037367 WO2017007577A1 (en) | 2015-07-08 | 2016-06-14 | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016910A true MX2017016910A (es) | 2018-08-15 |
Family
ID=57686013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016910A MX2017016910A (es) | 2015-07-08 | 2016-06-14 | Tratamiento del deterioro del modo de andar y de las extremidades y del trastorno de procesamiento de la corteza pre-frontal. |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3319603B1 (enExample) |
| JP (2) | JP6930969B2 (enExample) |
| CN (1) | CN108025003B (enExample) |
| CA (1) | CA2991529C (enExample) |
| MX (1) | MX2017016910A (enExample) |
| WO (1) | WO2017007577A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2991529C (en) * | 2015-07-08 | 2021-01-05 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2157880A (en) | 1937-01-22 | 1939-05-09 | Electrical Res Prod Inc | Recording system |
| US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
| US4145083A (en) | 1977-06-17 | 1979-03-20 | Urban Frank K | Therapeutic chair for cerebral palsy child |
| US4844075A (en) | 1984-01-09 | 1989-07-04 | Pain Suppression Labs, Inc. | Transcranial stimulation for the treatment of cerebral palsy |
| GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
| US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
| US6121261A (en) | 1997-11-19 | 2000-09-19 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| RU2185106C1 (ru) | 2001-07-12 | 2002-07-20 | Свадовский Александр Игоревич | Способ нейрохирургического лечения детского церебрального паралича |
| CA2538864C (en) * | 2003-09-17 | 2013-05-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
| US8952895B2 (en) * | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
| WO2005063248A1 (en) | 2003-12-22 | 2005-07-14 | Sepracor Inc. | Modafinil combination therapy for improving sleep quality |
| US20050182097A1 (en) | 2003-12-30 | 2005-08-18 | Zeldis Jerome B. | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
| CA2595159A1 (en) * | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| EP2338881A1 (en) | 2005-02-23 | 2011-06-29 | Prexa Pharmaceuticals, Inc. | Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications |
| CA2686155C (en) * | 2006-05-22 | 2016-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Pharmacological treatment of cognitive impairment |
| EP1985276A1 (en) | 2007-04-26 | 2008-10-29 | Merz Pharma GmbH & Co. KGaA | Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy |
| US20110270345A1 (en) | 2007-08-11 | 2011-11-03 | Johns Hopkins University | Focal noninvasive stimulation of the sensory cortex of a subject with cerebral palsy |
| US20110207718A1 (en) * | 2008-08-06 | 2011-08-25 | Gosforth Centre (Holdings) Pty Ltd. | Compositions and methods for treating psychiatric disorders |
| WO2011011528A1 (en) * | 2009-07-23 | 2011-01-27 | Musc Foundation For Research Development | Isopropylphenidate for the treatment of attention-deficit/hyperactivity disorder and fatigue-related disorders and conditions |
| CA2786026A1 (en) | 2010-01-07 | 2011-07-14 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| WO2011109389A2 (en) * | 2010-03-01 | 2011-09-09 | Boston-Power, Inc. | Thermal sensor device with average temperature and hot spot feedback |
| EP2544688B1 (en) * | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
| US8287903B2 (en) | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| WO2012158892A2 (en) * | 2011-05-19 | 2012-11-22 | Bruce Roseman | A method of treating apraxia of speech in children |
| US20140163070A1 (en) | 2012-05-17 | 2014-06-12 | Bruce Roseman | Treatment for cerebral palsy impaired speech in children |
| US9682073B2 (en) * | 2011-05-19 | 2017-06-20 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder gait and limb impairments treatment |
| US8883815B2 (en) | 2011-05-19 | 2014-11-11 | Gilrose Pharmaceuticals, Llc | Treatment for cerebral palsy impaired speech in children |
| KR20130016127A (ko) * | 2011-08-04 | 2013-02-14 | 의료법인 성광의료재단 | 외상성 뇌손상의 치료 |
| SG11201403023WA (en) * | 2011-12-08 | 2014-07-30 | Apos Medical & Sports Technologies Ltd | Device and methods for treating neurological disorders |
| EP2705841A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| US9305307B2 (en) * | 2013-07-15 | 2016-04-05 | Google Inc. | Selecting content associated with a collection of entities |
| CN106458894A (zh) * | 2013-11-08 | 2017-02-22 | 诺兰可股份有限公司 | 用于制备哌甲酯及其药用盐的方法 |
| CA2991529C (en) | 2015-07-08 | 2021-01-05 | Gilrose Pharmaceuticals, Llc | Pre-frontal cortex processing disorder, gait and limb impairment treatment |
-
2016
- 2016-06-14 CA CA2991529A patent/CA2991529C/en active Active
- 2016-06-14 JP JP2018520374A patent/JP6930969B2/ja active Active
- 2016-06-14 CN CN201680052229.7A patent/CN108025003B/zh active Active
- 2016-06-14 WO PCT/US2016/037367 patent/WO2017007577A1/en not_active Ceased
- 2016-06-14 EP EP16821790.9A patent/EP3319603B1/en active Active
- 2016-06-14 MX MX2017016910A patent/MX2017016910A/es unknown
-
2021
- 2021-02-08 JP JP2021018221A patent/JP7350794B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108025003A (zh) | 2018-05-11 |
| EP3319603A4 (en) | 2019-03-13 |
| JP2021088571A (ja) | 2021-06-10 |
| JP6930969B2 (ja) | 2021-09-01 |
| EP3319603B1 (en) | 2021-11-17 |
| EP3319603A1 (en) | 2018-05-16 |
| CA2991529C (en) | 2021-01-05 |
| CN108025003B (zh) | 2021-07-13 |
| JP7350794B2 (ja) | 2023-09-26 |
| CA2991529A1 (en) | 2017-01-12 |
| WO2017007577A1 (en) | 2017-01-12 |
| JP2018521127A (ja) | 2018-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL324089A (en) | Methods for treating Fabry disease patients with kidney defects | |
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| TW201613636A (en) | Methods of treating Alzheimer's Disease | |
| EP3600374C0 (en) | TREATMENT OF A RESPIRATORY INFECTION | |
| ZA201705874B (en) | Nk-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat | |
| IL269083A (en) | Methods for preventing and treating heart disease | |
| MX2018007307A (es) | Conjugados de peptidos y oligonucleotidos. | |
| PH12017501993A1 (en) | Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy | |
| SG11201702766YA (en) | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv) | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| EP4069438A4 (en) | SKIN TREATMENT SYSTEM | |
| PH12019550183A1 (en) | Treatment of infant colic | |
| MX2017016910A (es) | Tratamiento del deterioro del modo de andar y de las extremidades y del trastorno de procesamiento de la corteza pre-frontal. | |
| EP3847666A4 (en) | SYSTEM FOR PROVIDING SHARED DECISION MAKING FOR PATIENT TREATMENT OPTIONS | |
| NZ729803A (en) | A method for the treatment of motor neuron diseases | |
| MY205171A (en) | Methods of treatment of hypertriglyceridemia | |
| EP3681410A4 (en) | HEART TREATMENT SYSTEM AND METHOD | |
| PH12018500682A1 (en) | Oxa-diazaspiro compounds having activity against pain | |
| PT4062916T (pt) | Tratamento de pacientes com fabry com mutações específicas | |
| MA40574A (fr) | Traitement de maladies fibrotiques | |
| CA211610S (en) | Skin treatment system | |
| MX2018013885A (es) | Métodos de tratamiento de enfermedades asociadas con células linfoides innatas del grupo 3 (cli3). | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders |